Allen Institute for Immunology’s Post

The Seattle STRIDE study 🔬, a groundbreaking collaboration between Seattle Children's and the Allen Institute for Immunology, is poised to revolutionize the treatment of pediatric IBD. By harnessing the power of deep immune profiling, researchers are gaining an unprecedented understanding of the complex molecular mechanisms underlying this disease. 🦠 This innovative approach allows scientists to analyze individual immune cells and molecules within tissues collected during routine hospital visits. By tracking changes over time, they can identify specific patterns associated with disease progression and treatment response. This wealth of data is providing researchers with a roadmap to develop targeted therapies that address the root causes of IBD, offering hope for improved outcomes and a brighter future for children affected by this debilitating condition. #SeattleChildrens #AllenInstituteforImmunology #IBD #pediatricIBD #clinicaltrials #research #deepimmuneprofiling #immunology

This recent study highlights the urgent need for research into pediatric post-acute sequelae of SARS-CoV-2 (PASC), or long COVID. While most studies have focused on adults, we know even less about how this complex condition affects children. We aim to change that by investigating which symptoms correlate with specific activated ancestral genes in long COVID cases. Our upcoming IRB study will focus on uncovering the underlying mechanisms of long COVID, including its overlap with neurodegenerative diseases like the Parkinsonian diseases. We’re using social media to reach out to those already working in this space and welcome anyone who is interested in collaborating or sharing insights. If you or someone in your network is studying long COVID or related fields, please connect with us via LinkedIn or through our website at FBBBio.com. #dementia #alzheimers #venturecapital #angelinvestor #cancer #hivaids  #bioOS #biotechnology #diagnostics #innovation #technology #management #startups #liquidbiopsy #neurodegenerativediseases #multiplesclerosis #parkinsonsdisease #alzheimersdisease #longhaulers #longcovid #humangenome #onetestonelife #longevity #artificialintelligence #rna #rnaseq #personalizedprevention #PersonalizedMedicine #ClinicalResearch #COVID19 #Parkinsons https://lnkd.in/ePWbVwhW 

“Systems immunology approach to long COVID” Systems immunology is a compilation of strategies for measuring a broad range of immunological assays as a powerful way of making the human immune systems more interpretable and understandable as a whole by discovering the relationships between the phenomena, factors, or mechanisms involved in diseases. This is vital for diagnosing and treating long COVID, which, like myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), is a multifactorial disease that cannot be diagnosed by a single laboratory test nor treated with a single medication. Long COVID is now recognized as a separate disorder that follows soon after an initial infection with SARS-CoV-2 and may last for an indefinite period, with a wide range of persisting, returning or even new but related symptoms that involve different tissues and organs, including respiratory, cardiac, vascular, gastrointestinal, musculoskeletal, neurological, endocrine and systemic. Along with this multiplicity of symptoms, there are also several mechanisms that work together to bring about this disease. For more on this abstract or to register for our Fall Conference, visit the link below: https://lnkd.in/dgpPHZRy #LongCovid #MAPS #Immunology #CME #pediatrics #specialneeds #medical

While the survival of children with cancer has improved over time, infection remains a major morbidity and mortality risk. The Karius team together with Nicole Coufal, Samuel R. Dominguez, Kevin Messacar, and Frederick D. Goldman published a review of the state of our understanding of the value of the infectious disease diagnostic procedures currently in use in this population. The review highlights the lack of published data on infectious disease testing in pediatric oncology patients, and the need for well-designed clinical impact and cost-effectiveness studies of both existing and novel diagnostic platforms. Such studies are necessary to optimize diagnostic and antimicrobial stewardship, leading to improvement in patient outcomes. https://hubs.li/Q02v26DV0 #pediatrics #infection #infections #diagnostics #microbiology #oncology #immunocompromised #clinicalimpact #costeffectivness #antimicrobialstewardship

Providing a Snapshot of #Pediatric Patients and Lessons Learned from the NEPTUNE Cohort Study New research from the #NephroticSyndrome Study Network (NEPTUNE): https://lnkd.in/gDX2w6BF #PrimaryGlomerularDiseases are a group of conditions that affect #kidney function by attacking the #glomeruli, which are kidney structures responsible for filtering the blood and removing waste in urine. NEPTUNE is a #RareDisease network that focuses on patients with #MinimalChangeDisease, #FocalSegmentalGlomerulosclerosis, and #MembranousNephropathy. The NEPTUNE longitudinal cohort study collects detailed demographic, clinical, histopathologic, genomic, transcriptomic, and metabolomic data from patients of all ages to develop a molecular classification for these disorders. In this review, researchers provide a snapshot of pediatric patients and lessons learned from the NEPTUNE cohort study. The team summarizes key observations and describes the development of the NEPTUNE Match program, which provides individualized guidance about potential clinical trial participation based on the molecular characterization and non-invasive biomarker profile of each patient. Authors note that NEPTUNE has proven to be an invaluable asset in the study of glomerular diseases in patients of all ages, including children and adolescents.

On February 29, we will observe World Rare Disease Day, a day dedicated to raising awareness about rare diseases and the individuals and families affected by them. Rare diseases—despite their individual rarity—collectively impact millions of people worldwide, often leading to significant challenges in diagnosis, treatment and support. Clinical research is crucial for developing effective treatments for these diseases and we help make a difference through our support of complex and novel clinical trials. To achieve true equity, it's necessary to acknowledge the unique circumstances of each participant and allocate resources accordingly. In partnership with drug developers, and our Rare Diseases, Advanced Therapies and Pediatrics Team (RAPT)—must consider how we conduct clinical trials and the requirements placed on rare disease participants. #rarediseaseday #showyourrare #fortrea

🚨 European Neonatal RBC Transfusion Practices: Key Findings and Updated Recommendations 🚨 In the 2022-2023 "Red Blood Cell Transfusion in European Neonatal Intensive Care Units" study, significant insights into transfusion practices for preterm infants were gathered across 64 NICUs in 22 European countries. This study, conducted after the publication of the ETTNO and TOP trials, explored current clinical integration of restrictive versus liberal transfusion thresholds. 🔹 Key Finding by Houben et al. 2024 (Francesco Cardona for Austria): Study Population: Among 1143 preterm infants (56.1% male), the median gestational age was 28 weeks, with a median birth weight of 1030 g. RBC Transfusion Prevalence: By day 28, 36.5% of infants had received at least one RBC transfusion, with 903 transfusions given in total. Pretransfusion Hemoglobin (Hb) Levels: 44.4% of transfusions had pretransfusion Hb levels below restrictive thresholds (ETTNO), while 48.3% were between restrictive and liberal thresholds. The proportions under TOP guidelines were 36.4% and 56.1%, respectively. Adverse Events: Rare, with only two transfusion-associated adverse events reported. 🔹 Recommendations from Deschmann et al., 2024: A restrictive transfusion strategy is conditionally recommended for preterm neonates (<30 weeks' gestation), supported by moderate certainty of evidence. Specific hemoglobin thresholds vary based on the neonate's respiratory support status: Neonates on Respiratory Support: Week 1: Hb ≥11 g/dL Week 2: Hb ≥10 g/dL Week 3+: Hb ≥9 g/dL Neonates on Minimal or No Respiratory Support: Week 1: Hb ≥10 g/dL Week 2: Hb ≥8.5 g/dL Week 3+: Hb ≥7 g/dL #Neonatology #RBCTransfusions #ClinicalGuidelines #NICU #Pediatrics #HealthcareInnovation #PatientSafety https://lnkd.in/d8jhU-k7

Today, as we mark International #RareDiseaseDay, I would like to remind the staggering reality: over 200 million children worldwide grapple with rare diseases. At Pierre Fabre Laboratories, we stand committed to making a tangible difference in their lives. We believe in action that illustrate our dedication. 👉 Collaborating with EspeRare foundation, we're pioneering an innovative in-utero therapy, a real hope for young patients battling XLHED. This rare genetic disorder, impacting 500 infants annually, affects not just their sweat glands, skin and hair, but also their teeth. 👉 In the realm of oncology, our alliance with Atara Biotherapeutics has led to a major step forward in treating EBV+ PTLD, a rare post-transplant lymphoma. Approved by the EMA, this treatment, honored with the 2023 Prix Galien France 🏆, is a lifeline for numerous children. 👉 Teaming up with Bordeaux University Hospital, we've developed a revolutionary drug to manage infantile hemangiomas, a benign tumor that afflicts 4.5% of infants under one year old, offering them a brighter, healthier future. 👉 Through our partnership with Association Ichtyose France and patient associations, we're tirelessly gathering crucial data to enhance the lives of those affected by ichthyosis, a debilitating skin disorder impacting around 1% of individuals and profoundly affecting their quality of life. Together, let's amplify our efforts in the battle against rare pediatric diseases! 💪 https://lnkd.in/dhm3Ypg9 cc. Nuria Perez Cullell #PierreFabre #RareDiseases #Medical #Innovation #NewWaysToCare #Pediatry

🚨 Early Detection Saves Lives 🚨 Primary care providers play a crucial role in the early diagnosis of #retinoblastoma and related second cancers. As the first point of contact for concerned parents and survivors, they’re essential in spotting symptoms and ensuring timely referrals. In our latest blog post, World Eye Cancer Hope CEO Abby White explores the challenges faced by primary care providers, their critical role in early detection, and the need for targeted education to enhance their ability to recognize these signs. Check it out to learn more about how we can support primary care providers in saving lives! #EarlyDetection #PrimaryCare #Pediatrics #PediatricOncology #FamilyPhysician #EyeCare #CancerPrevention #ChildhoodCancer https://lnkd.in/eiAvyYpn

🧬A new study by Karvas et al. (2023) introduces a powerful model of the human placenta using stem-cell-derived trophoblast organoids (SC-TOs). These 3D organoids provide critical insights into placental development and its susceptibility to viral infections like SARS-CoV-2 and Zika virus. 🔍 Why this matters: Realistic Modeling: SC-TOs accurately replicate the villous architecture and hormone secretion patterns of early pregnancy, addressing the limitations of prior 2D models. * Disease Susceptibility: They reveal that while SARS-CoV-2 shows limited infectivity, Zika virus readily invades these early placental cells, shedding light on potential risks for fetal development. *Research Potential: With single-cell transcriptomics, the organoids highlight key pathways of cell differentiation and X-chromosome inactivation during placental development. This cutting-edge research offers a patient-specific platform to study maternal-fetal interactions, promising to accelerate breakthroughs in reproductive health and infectious disease research. 🚀 If you want to know more: https://lnkd.in/eq2X_Qfm